Translational roadmap for regenerative therapies of eye disease

Leonard A Levin; Michael F Chiang; Michael A Dyer; Thomas N Greenwell; Clive N Svendsen; Santa J Tumminia; Russell N Van Gelder; Rachel O Wong

doi:10.1016/j.medj.2023.06.005

Translational roadmap for regenerative therapies of eye disease

Med. 2023 Sep 8;4(9):583-590. doi: 10.1016/j.medj.2023.06.005.

Authors

Leonard A Levin¹, Michael F Chiang², Michael A Dyer³, Thomas N Greenwell⁴, Clive N Svendsen⁵, Santa J Tumminia⁴, Russell N Van Gelder⁶, Rachel O Wong⁷

Affiliations

¹ Department of Ophthalmology and Visual Sciences, McGill University, Montreal, QC H3A2B4, Canada; Department of Neurology & Neurosurgery, McGill University, Montreal, QC H3A2B4, Canada. Electronic address: leonard.levin@mcgill.ca.
² National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA; National Library of Medicine, National Institutes of Health, Bethesda, MD 20894, USA.
³ Department of Developmental Neurobiology, St. Jude's Research Hospital, Memphis, TN 38105, USA.
⁴ National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.
⁵ Board of Governors Regenerative Medicine Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA; Department of Biomedical Sciences, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA.
⁶ Department of Ophthalmology, University of Washington School of Medicine, Seattle, WA 98195, USA; Department of Biological Structure, University of Washington School of Medicine, Seattle, WA 98195, USA; Department of Pathology and Laboratory Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA; Roger and Angie Karalis Johnson Retina Center, University of Washington School of Medicine, Seattle, WA 98195, USA.
⁷ Department of Ophthalmology, University of Washington School of Medicine, Seattle, WA 98195, USA; Department of Biological Structure, University of Washington School of Medicine, Seattle, WA 98195, USA.

Abstract

The translation of regenerative therapies to neuronal eye diseases requires a roadmap specific to the nature of the target diseases, patient population, methodologies for assessing outcome, and other factors. This commentary focuses on critical issues for translating regenerative eye therapies relevant to retinal neurons to human clinical trials.

MeSH terms

Eye Diseases* / therapy
Humans
Retinal Neurons*
Translations

Abstract

MeSH terms

Grants and funding